BRAINSTORM CELL THERAPEUTICS INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that BRAINSTORM CELL THERAPEUTICS INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($10.31M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($11.62M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($17.19M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($24.28M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($24.46M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($31.81M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($23.25M) | Feb 4, 2021 |
| FY2019 | Dec 31, 2018 | ($13.95M) | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | ($4.95M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($4.98M) | Mar 8, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.95M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($11.69M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($21.44M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($24.82M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($24.54M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($31.68M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($23.00M) | Feb 4, 2021 |
| FY2019 | Dec 31, 2018 | ($14.06M) | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | ($5.00M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($5.08M) | Mar 8, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.18M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $4.65M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $10.75M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $13.96M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $15.24M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $22.33M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $17.20M | Feb 4, 2021 |
| FY2019 | Dec 31, 2018 | $8.29M | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | $977.0K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $2.25M | Mar 8, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.98M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($9.09M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($20.46M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($19.32M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($26.27M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($35.19M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($11.25M) | Feb 4, 2021 |
| FY2019 | Dec 31, 2018 | ($12.39M) | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | ($2.36M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($5.86M) | Mar 8, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $18.0K | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | $29.0K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $330.0K | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $378.0K | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $473.0K | Feb 4, 2021 |
| FY2019 | Dec 31, 2018 | $369.0K | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | $180.0K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $103.0K | Mar 8, 2018 |
| FY2016 | Dec 31, 2015 | $45.0K | Mar 29, 2017 |
| FY2015 | Dec 31, 2014 | $161.0K | Mar 9, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.02M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $1.83M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $4.21M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $8.45M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $29.28M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $51.26M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $6.53M | Feb 4, 2021 |
| FY2019 | Dec 31, 2018 | $11.23M | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | $11.42M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $10.77M | Mar 8, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.01M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $9.60M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $9.07M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $11.47M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $9.94M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $15.80M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $18.76M | Feb 4, 2021 |
| FY2019 | Dec 31, 2018 | $6.21M | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | $5.54M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $864.0K | Mar 8, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.99M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($7.76M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | ($4.86M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | ($3.02M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $19.34M | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | $35.46M | Mar 30, 2023 |
| FY2021 | Dec 31, 2019 | ($12.22M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2018 | $5.02M | Feb 4, 2021 |
| FY2019 | Dec 31, 2017 | $5.88M | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $9.90M | Apr 1, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($236.94M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($226.64M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($215.01M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($197.82M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($173.54M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($149.09M) | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | ($117.28M) | Feb 4, 2021 |
| FY2019 | Dec 31, 2018 | ($94.02M) | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | ($80.08M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($75.12M) | Mar 8, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $29.0K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $187.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $1.30M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $772.0K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $18.86M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $37.83M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | $536.0K | Feb 4, 2021 |
| FY2019 | Dec 31, 2018 | $942.0K | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | $2.48M | Apr 1, 2019 |
| FY2018 | Dec 31, 2016 | $547.0K | Apr 1, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (6) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | (1) | Mar 28, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (6) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | (1) | Mar 28, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 11.03M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 6.14M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 4.03M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 36.69M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 36.40M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 35.16M | Mar 28, 2022 |
| FY2020 | Dec 31, 2019 | 23.17M | Feb 4, 2021 |
| FY2019 | Dec 31, 2018 | 20.76M | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | 18.98M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 18.69M | Mar 8, 2018 |